Xponance LLC Has $29.15 Million Stock Position in Gilead Sciences, Inc. $GILD

Xponance LLC boosted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 237,491 shares of the biopharmaceutical company’s stock after buying an additional 12,516 shares during the quarter. Xponance LLC’s holdings in Gilead Sciences were worth $29,150,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. Paulson Wealth Management Inc. grew its position in Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock worth $477,000 after acquiring an additional 67 shares in the last quarter. Essex Financial Services Inc. grew its position in Gilead Sciences by 0.9% in the fourth quarter. Essex Financial Services Inc. now owns 7,724 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 71 shares in the last quarter. Alpha Cubed Investments LLC grew its position in Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock worth $812,000 after acquiring an additional 75 shares in the last quarter. Personal CFO Solutions LLC grew its position in Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock worth $561,000 after acquiring an additional 76 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its position in Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $546,000 after acquiring an additional 76 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on GILD. Morgan Stanley dropped their price target on Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Mizuho lifted their price target on Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Citigroup lifted their price target on Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Gilead Sciences in a research report on Tuesday. Twenty-five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $156.93.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the chief financial officer owned 173,191 shares of the company’s stock, valued at $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 68,000 shares of company stock worth $9,047,570. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Up 3.6%

Shares of NASDAQ GILD opened at $125.87 on Friday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The firm has a market capitalization of $156.28 billion, a price-to-earnings ratio of 17.15 and a beta of 0.31. The stock has a 50 day moving average price of $133.46 and a 200 day moving average price of $134.34. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.Gilead Sciences’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s payout ratio is presently 44.69%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported positive topline Phase 3 results for their once-weekly oral HIV regimen (islatravir + lenacapavir), reinforcing optimism around Gilead’s HIV franchise and future growth. Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?
• Positive Sentiment: Bernstein reiterated a Buy rating on Gilead, which can help sentiment by signaling confidence in the company’s outlook. Gilead Sciences (GILD) Gets a Buy from Bernstein
• Positive Sentiment: Options activity skewed bullish, with unusually high call buying, suggesting traders were positioning for more upside in GILD.
• Positive Sentiment: Recent articles also highlighted progress in Gilead’s pipeline, including Livdelzi Phase 3 results and strength in its HIV franchise, both of which support the stock’s growth narrative. Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development
• Neutral Sentiment: The Gilead Foundation announced a roughly $3 million, three-year commitment with the National AIDS Memorial to expand HIV/AIDS education and community leadership, a reputationally positive move but not a direct earnings driver. National AIDS Memorial and the Gilead Foundation Launch Major Investment…
• Negative Sentiment: Erste Group Bank slightly lowered its FY2026 EPS estimate for Gilead, reflecting a modestly less optimistic near-term profit outlook.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.